Numinus Wellness Inc. specializes in psychedelic-assisted therapy training and psychotherapy services in North America. While it boasts a relatively strong gross margin of 48.3%, its negative EBITDA and net margins indicate significant operational challenges, with a current ratio of 0.61 suggesting potential liquidity issues. The low market cap of $16.03M and stagnant stock price raise concerns about investor confidence, despite the growing interest in the psychedelic therapy sector. Overall, Numinus faces hurdles in profitability and liquidity that could impact its growth potential.
Loading financial metrics...
Company has $823K in cash but burned $2.4M last quarter. At this burn rate, only 0.3 quarters of runway remain without additional financing.
Company posted a loss of $-14.6M over the last year, representing -326.5% of revenue.
Low debt-to-revenue ratio of -51.9% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical Care Facilities companies of a similar size
Based on 2025-Q2 (May 31, 2025)